EXENATIDE (BYETTA) VS PRAMLINTIDE (SYMLIN): ROLE IN POST-PRANDIAL HYPERGLYCEMIA.

Trial Profile

EXENATIDE (BYETTA) VS PRAMLINTIDE (SYMLIN): ROLE IN POST-PRANDIAL HYPERGLYCEMIA.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Exenatide (Primary) ; Pramlintide (Primary) ; Insulin; Insulin aspart; Insulin detemir; Insulin glargine; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Feb 2012 Planned End Date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top